IL-6 inhibitors provide therapeutic benefits in treating COVID-19 patients
Multiple systematic reviews and clinical studies indicate that interleukin-6 inhibitors, such as tocilizumab and sarilumab, provide therapeutic benefits and reduce mortality in patients with severe COVID-19.
The retrieved literature contains several systematic reviews, meta-analyses, and clinical papers demonstrating that IL-6 inhibitors reduce mortality and improve clinical outcomes in COVID-19 patients, especially those with severe disease or cytokine release syndrome. No papers refute this claim.
Po-Lin Chen, N. Lee, Cong-Tat Cia, W. Ko, P. Hsueh. A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. 2020. https://doi.org/10.3389/fphar.2020.584956
A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs notes that small sample studies demonstrate interleukin-6 inhibitors may improve clinical outcomes in COVID-19.
See more details
R. Pinzon, V. Wijaya, Ranbebasa Bijak Buana. Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. 2021. https://doi.org/10.1016/j.jiph.2021.06.004
Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis reveals a significant reduction in mortality with tocilizumab and sarilumab.
Ying Wang, Kun Zhu, R. Dai, Ruiqin Li, Miao Li, Xin Lv, Qian Yu. Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review. 2022. https://doi.org/10.3389/fphar.2021.804250
Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review indicates that tocilizumab and other IL-6 inhibitors can reduce mortality in severe COVID-19 patients.
M. Hashizume. Outlook of IL-6 signaling blockade for COVID-19 pneumonia. 2020. https://doi.org/10.1186/s41232-020-00134-7
Outlook of IL-6 signaling blockade for COVID-19 pneumonia discusses how IL-6 signal inhibitors provide efficacy in hospitalized populations when combined with standard of care.
S. Zyryanov, O. Butranova, A. Abramova. Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19. 2024. https://doi.org/10.37489/2588-0519-2024-1-4-16
Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19 states that blocking IL-6 is crucial for improving clinical outcomes and reducing death in severe COVID-19.
E. Kalinina, I. V. Lekareva, M. Zvonorenko, A. L. Emelianova, I. V. Kostryukova, E. V. Scherbinina, A. Babaeva. Rheumatic diseases and coronavirus infection: levilimab use experience. 2021. https://doi.org/10.33667/2078-5631-2021-16-7-12
Rheumatic diseases and coronavirus infection: levilimab use experience confirms the high efficacy and good tolerability of IL-6 receptor inhibitors in treating coronavirus pneumonia.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt